PD-L1-ATRi / DCx Biotherapeutics - LARVOL DELTA

Novel ATR inhibitor payloads for antibody-drug conjugates targeting PD-L1 (AACR 2026) - "Preclinical in vivo studies in mice demonstrate robust efficacy and selectivity with PD-L1-ATRi as single agent relative to IgG-ATRi. The in vitro and in vivo data presented herein demonstrate the efficacy of an ADC with an ATRi mono-payload and illustrate the potential for combinations with standard of care chemotherapeutic agents such as gemcitabine or PARP inhibitors."

ADC • IO biomarker • Colon Cancer • Colorectal Cancer • Oncology • Solid Tumor